No 2020:9: Cancer i Sverige – Hur mycket beror på påverkbara riskfaktorer?
Adam Fridhammar, Thomas Hofmarcher and Sofie Persson
No 2020:8: Disease burden associated with Covid-19 in Sweden – QALYs lost due to excess mortality
Ulf Persson, Sara Olofsson and George Keel
No 2020:7: Quality-of-Life in the Swedish general population during Covid-19 – based on measurement pre- and post pandemic outbreak
Ulf Persson and Sara Olofsson
No 2020:6: The Cost of Cancers of the Digestive System in Europe
Thomas Hofmarcher and Peter Lindgren
No 2020:5: Hälsoekonomisk analys av riktad screening för lungcancer av rökande och före detta rökande kvinnor i Region Stockholm
Adam Fridhammar and Katarina Steen Carlsson
No 2020:4: Produktionsbortfall – en metodologisk genomgång och beräkningar
Sara Olofsson and Frida Hjalte
No 2020:3: Opportunities and challenges of an innovative payment model for Advanced Therapy Medicinal Products in Sweden -A hypothetical example in the treatment of β-thalassemia
Ulf Persson and Jenny Norlin
No 2020:2: Patient pathways in the treatment of opioid drug dependency – A register-based real world analysis using regional healthcare registers
Sofia Löfvendahl and Katarina Steen Carlsson
No 2020:1: Samhällets kostnader för spelproblem i Sverige
Thomas Hofmarcher and Ulf Persson
Questions (including download problems) about the papers in this series should be directed to Annette Persson Dietmann ()
Report other problems with accessing this service to Sune Karlsson ().
This page generated on 2024-10-15 09:52:41.